Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains

Helicobacter

Volumn 17, Issue 4, 2012, Pages 269-276

  Molina Infante, Javier ^a   Pazos Pacheco, Carmen ^a   Vinagre Rodriguez, Gema ^a   Perez Gallardo, Belen ^a   Dueñas Sadornil, Carmen ^a   Hernandez Alonso, Moisés ^a   Gonzalez Garcia, Guadalupe ^a   Mateos Rodriguez, Jose M ^a   Fernandez Bermejo, Miguel ^a   Gisbert, Javier P ^b  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Clarithromycin resistance; Concomitant therapy; Helicobacter pylori; Nonbismuth quadruple therapy; Sequential therapy; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; UREA C 13;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; CLARITHROMYCIN RESISTANT HELICOBACTER PYLORI; CLARITHROMYCIN SUSCEPTIBLE HELICOBACTER PYLORI; CONTROLLED STUDY; DIGESTIVE TRACT ENDOSCOPY; DRUG EFFICACY; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SMOKING; STOMACH BIOPSY; STOMACH ULCER; TREATMENT DURATION; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 84863585858     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00947.x     Document Type: Article

References (36)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
2. Chey WD, Wong BC. American College of Gastroenterology Guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
3. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-31.
4. Megraud F. H pylori antibiotic resistance: prevalence, importance and advantages in testing. Gut 2004;53:1374-84.
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing of antibiotic resistance. Gut 2010;59:1143-53.
6. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007;370:1010-2.
7. Zullo A, De Francesco V, Hassan C, Moroni S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7.
8. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31.
9. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41-53.
10. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79.
11. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, Sorrentino D, Gasbarrini G. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782-9.
12. Gisbert JP, Calvet X, O'Connor A, Megraud F, O′Morain C. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25.
13. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-18.
14. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2011;34:604-17.
15. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with 4 drugs are equally effective for H. pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41.
16. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C, Mateos-Rodriguez JM, Gonzalez-Garcia G, Abadía EG, Gisbert JP. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010;31:1077-84.
17. King A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother 2001;48:77-80.
18. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.
19. Alarcon T, Baquero M, Domingo D, Lopez-Brea M, Royo G. Diagnostico microbiologico de la infeccion por Helicobacter pylori. In: Cercenado E, Cantón R, eds. Procedimientos en Microbiologia Clinica. Madrid: Sociedad Española de Enfermedades Infecciosas y Microbiologia Clínica, 2004;Chapter 17.
20. Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniu N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four drug, three-antibiotic, non-bismuth containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter 2012;17:49-53.
21. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant and 10-day sequential therapies Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;377:905-13.
22. Gisbert JP, Nyssen OP, McNicholl A, Megraud F, Savarino V, Oderda G, Fallone C, Fischbach L, Bazzoli F. Meta-analysis of sequential vs. standard triple therapy for Helicobacter pylori eradication. Helicobacter 2011;16 (Suppl 1):131.
23. Choi WH, Park DI, Oh SJ, et al. Effectiveness of 10day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008;51:280-4.
24. Remes-Troche JM, Alarcon-Rivera G, Ramos-de la Medina A, De la Cruz Patiño E, Reyes Huertas J, Roesch FB. Sequential therapy vs standard triple therapy as treatment of Helicobacter pylori infection. A prospective, randomized, parallel-group, open-label study in Mexico. Gastroenterology 2010;138:S-336.
25. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010;59:1465-70.
26. Sirimontaporn N, Thong-Ngan M, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori in Thailand. Am J Gastroenterol 2010;105:1071-5.
27. Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK. Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol 2011;26:825-8.
28. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
29. Megraud F, Kist M, Lopez Brea M, Hirschl A, Andersen LP, Glupczynski Y, Hirschl A. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008-2009. Gastroenterology 2011;140(suppl 1):S-312.
30. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008;68:725-36.
31. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001;13:1303-7.
32. Graham DY. Helicobacter pylori eradication therapy research: ethical issues and description of the results. Clin Gastroenterol Hepatol 2010;8:1032-6.
33. Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 2001;17:39-44.
34. Hsu PI, Wu DC, Wu YC, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7days. Helicobacter 2011;16:139-45.
35. Hsu PI, Wu DC, Wu YC, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14days?. Helicobacter 2011;16:146-52.
36. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011;377:905-13.